Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Autologous keratinocytes are a patient's own skin cells harvested, expanded in vitro, and grafted onto damaged skin to restore the epidermis. This method is used for treating extensive burns, chronic wounds, and certain genetic or pigmentary skin disorders. The keratinocytes, particularly those with stem cell-like properties, reconstitute a functional stratified epithelium after transplantation. EGFR signaling, integrins, and Wnt signaling are key pathways involved in successful regeneration. The grafts may contain keratinocytes, melanocytes, and sometimes fibroblasts. Advantages include low rejection risk and the ability to cover large areas from small biopsies. Limitations include the need for specialized lab facilities and a time lag for preparation.
Ex vivo expansion and transplantation of autologous keratinocytes to regenerate the epidermis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Autologous Keratinocytes.